Healthcare–associated Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?
The 7 major healthcare–associated pneumonia markets reached a value of US$ 666.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 983.9 Million by 2034, exhibiting a growth rate (CAGR) of 3.61% during 2024-2034.
The healthcare–associated pneumonia market has been comprehensively analyzed in IMARC’s new report titled "Healthcare–associated Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?". Healthcare-associated pneumonia (HCAP) refers to a type of pneumonia that occurs due to prior contact with a healthcare environment. It is associated with the presence of several risk factors, including hospitalization in the past, home infusion therapy, dialysis, residing in a nursing center, immunocompromised state, etc. Bacterial infection, as opposed to a virus, is the predominant source of this form of pneumonia. Most symptoms of healthcare-associated pneumonia are equivalent to those seen in pneumonia developed outside hospitals. This condition is characterized by unpleasantness, a sense of unease, reduced appetite, cough with greenish or mucus-like phlegm, abdominal discomfort, and difficulty in breathing. Some other symptoms include sharp chest pain that exacerbates with inhalation and exhalation or coughing, as well as diminished blood pressure and an increased heart rate. The diagnosis of healthcare-associated pneumonia begins with a chest x-ray or CT scan to inspect the lungs and arterial blood gases to measure respiratory rate. It is accompanied by a sputum culture to detect the microorganisms causing pneumonia and a pulse oximetry test to monitor blood oxygen levels. The diagnosis also involves bronchoscopy, which is essential to avoid the possibility of an incorrect prognosis.
The increasing prevalence of chronic ailments, such as cardiac arrest, brain stroke, kidney failure, etc., which require surgical intervention and prolonged hospital stays is primarily driving the global healthcare-associated pneumonia market. Additionally, the inflating number of patients admitted to medical facilities who have antibacterial resistance owing to the excessive usage of antibiotics is also positively influencing the market growth. Moreover, the escalating utilization of combination therapy to treat HCAP since it reduces the chances of resistance developed by the bacteria and provides a broad spectrum of coverage is also creating a positive outlook for the market. In addition to this, the widespread adoption of point-of-care testing products owing to their associated benefits, including convenience, quicker diagnosis, and improved patient outcomes, is acting as a significant growth-inducing factor. Furthermore, the ongoing development of resistant strains and the increasing resultant need for newer antibiotics are promoting extensive R&D activities. This, in turn, is also augmenting the global market. Besides this, the emerging popularity of multiplex PCR-based platforms for diagnosing healthcare-associated pneumonia, as it offers high detection efficiency, thereby reducing cost and time, is further propelling the market growth. Additionally, the rising emphasis of the key players on developing efficient vaccines and antibiotics by utilizing advanced clinical solutions is also expected to drive the global healthcare-associated pneumonia market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the healthcare–associated pneumonia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool forhealthcare–associated pneumonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the healthcare–associated pneumonia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: ?2018-2023?
Market Forecast: ?2024-2034?
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the healthcare–associated pneumonia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the healthcare–associated pneumonia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current healthcare–associated pneumonia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the healthcare–associated pneumonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the healthcare–associated pneumonia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the healthcare–associated pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the healthcare–associated pneumonia patient pool (?2018-2023?) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of healthcare–associated pneumonia?
What will be the growth rate of patients across the seven major markets?
Healthcare–Associated Pneumonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for healthcare–associated pneumonia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the healthcare–associated pneumonia market?
The healthcare–associated pneumonia market has been comprehensively analyzed in IMARC’s new report titled "Healthcare–associated Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?". Healthcare-associated pneumonia (HCAP) refers to a type of pneumonia that occurs due to prior contact with a healthcare environment. It is associated with the presence of several risk factors, including hospitalization in the past, home infusion therapy, dialysis, residing in a nursing center, immunocompromised state, etc. Bacterial infection, as opposed to a virus, is the predominant source of this form of pneumonia. Most symptoms of healthcare-associated pneumonia are equivalent to those seen in pneumonia developed outside hospitals. This condition is characterized by unpleasantness, a sense of unease, reduced appetite, cough with greenish or mucus-like phlegm, abdominal discomfort, and difficulty in breathing. Some other symptoms include sharp chest pain that exacerbates with inhalation and exhalation or coughing, as well as diminished blood pressure and an increased heart rate. The diagnosis of healthcare-associated pneumonia begins with a chest x-ray or CT scan to inspect the lungs and arterial blood gases to measure respiratory rate. It is accompanied by a sputum culture to detect the microorganisms causing pneumonia and a pulse oximetry test to monitor blood oxygen levels. The diagnosis also involves bronchoscopy, which is essential to avoid the possibility of an incorrect prognosis.
The increasing prevalence of chronic ailments, such as cardiac arrest, brain stroke, kidney failure, etc., which require surgical intervention and prolonged hospital stays is primarily driving the global healthcare-associated pneumonia market. Additionally, the inflating number of patients admitted to medical facilities who have antibacterial resistance owing to the excessive usage of antibiotics is also positively influencing the market growth. Moreover, the escalating utilization of combination therapy to treat HCAP since it reduces the chances of resistance developed by the bacteria and provides a broad spectrum of coverage is also creating a positive outlook for the market. In addition to this, the widespread adoption of point-of-care testing products owing to their associated benefits, including convenience, quicker diagnosis, and improved patient outcomes, is acting as a significant growth-inducing factor. Furthermore, the ongoing development of resistant strains and the increasing resultant need for newer antibiotics are promoting extensive R&D activities. This, in turn, is also augmenting the global market. Besides this, the emerging popularity of multiplex PCR-based platforms for diagnosing healthcare-associated pneumonia, as it offers high detection efficiency, thereby reducing cost and time, is further propelling the market growth. Additionally, the rising emphasis of the key players on developing efficient vaccines and antibiotics by utilizing advanced clinical solutions is also expected to drive the global healthcare-associated pneumonia market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the healthcare–associated pneumonia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool forhealthcare–associated pneumonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the healthcare–associated pneumonia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: ?2018-2023?
Market Forecast: ?2024-2034?
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the healthcare–associated pneumonia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the healthcare–associated pneumonia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current healthcare–associated pneumonia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the healthcare–associated pneumonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the healthcare–associated pneumonia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the healthcare–associated pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the healthcare–associated pneumonia patient pool (?2018-2023?) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of healthcare–associated pneumonia?
What will be the growth rate of patients across the seven major markets?
Healthcare–Associated Pneumonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for healthcare–associated pneumonia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the healthcare–associated pneumonia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEALTHCARE–ASSOCIATED PNEUMONIA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 HEALTHCARE–ASSOCIATED PNEUMONIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEALTHCARE–ASSOCIATED PNEUMONIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 HEALTHCARE–ASSOCIATED PNEUMONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEALTHCARE–ASSOCIATED PNEUMONIA - UNMET NEEDS
10 HEALTHCARE–ASSOCIATED PNEUMONIA - KEY ENDPOINTS OF TREATMENT
11 HEALTHCARE–ASSOCIATED PNEUMONIA - MARKETED PRODUCTS
11.1 List of Healthcare–Associated Pneumonia Marketed Drugs Across the Top 7 Markets
11.1.1 Meropenem - Melinta Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Avibactam - Allergan
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ceftobiprole Medocaril - Basilea Pharmaceutica
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zerbaxa - Merck Sharp & Dohme
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 FETROJA – Shionogi & Co., Ltd.
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 HEALTHCARE–ASSOCIATED PNEUMONIA - PIPELINE DRUGS
12.1 List of Healthcare–Associated Pneumonia Pipeline Drugs Across the Top 7 Markets
12.1.1 Suvratoxumab - Shionogi & Co., Ltd.
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ceftolozane - Merck & Co
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Rifabutin - BioVersys
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Tosatoxumab - Aridis Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. HEALTHCARE–ASSOCIATED PNEUMONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 HEALTHCARE–ASSOCIATED PNEUMONIA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Healthcare–Associated Pneumonia - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Healthcare–Associated Pneumonia - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Healthcare–Associated Pneumonia - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Healthcare–Associated Pneumonia - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Healthcare–Associated Pneumonia - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Healthcare–Associated Pneumonia - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Healthcare–Associated Pneumonia - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Healthcare–Associated Pneumonia - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
15 HEALTHCARE–ASSOCIATED PNEUMONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 HEALTHCARE–ASSOCIATED PNEUMONIA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEALTHCARE–ASSOCIATED PNEUMONIA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 HEALTHCARE–ASSOCIATED PNEUMONIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEALTHCARE–ASSOCIATED PNEUMONIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 HEALTHCARE–ASSOCIATED PNEUMONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEALTHCARE–ASSOCIATED PNEUMONIA - UNMET NEEDS
10 HEALTHCARE–ASSOCIATED PNEUMONIA - KEY ENDPOINTS OF TREATMENT
11 HEALTHCARE–ASSOCIATED PNEUMONIA - MARKETED PRODUCTS
11.1 List of Healthcare–Associated Pneumonia Marketed Drugs Across the Top 7 Markets
11.1.1 Meropenem - Melinta Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Avibactam - Allergan
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ceftobiprole Medocaril - Basilea Pharmaceutica
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zerbaxa - Merck Sharp & Dohme
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 FETROJA – Shionogi & Co., Ltd.
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 HEALTHCARE–ASSOCIATED PNEUMONIA - PIPELINE DRUGS
12.1 List of Healthcare–Associated Pneumonia Pipeline Drugs Across the Top 7 Markets
12.1.1 Suvratoxumab - Shionogi & Co., Ltd.
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ceftolozane - Merck & Co
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Rifabutin - BioVersys
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Tosatoxumab - Aridis Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. HEALTHCARE–ASSOCIATED PNEUMONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 HEALTHCARE–ASSOCIATED PNEUMONIA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Healthcare–Associated Pneumonia - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Healthcare–Associated Pneumonia - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Healthcare–Associated Pneumonia - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Healthcare–Associated Pneumonia - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Healthcare–Associated Pneumonia - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Healthcare–Associated Pneumonia - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Healthcare–Associated Pneumonia - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Healthcare–Associated Pneumonia - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Healthcare–Associated Pneumonia - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Healthcare–Associated Pneumonia - Access and Reimbursement Overview
15 HEALTHCARE–ASSOCIATED PNEUMONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 HEALTHCARE–ASSOCIATED PNEUMONIA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
